

## Early pre-exposure prophylaxis (PrEP) discontinuation among pregnant and postpartum women: Implications for maternal PrEP roll out in South Africa

**Authors:** Dvora Leah Joseph Davey<sup>1,2,3</sup>, Rufaro Mvududu<sup>2</sup>, Nyiko Mashele<sup>2</sup>, Maia Lesosky<sup>2</sup>, Nehaa Khadka<sup>1</sup>, Jessica More<sup>2</sup>, Linda-Gail Bekker<sup>3</sup>, Pamina Gorbach<sup>1</sup>, Thomas J. Coates<sup>4</sup>, Landon Myer<sup>2</sup>, on behalf of PrEP-PP study team

1: Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America

2: Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

3: The Desmond Tutu Health Foundation, University of Cape Town, Cape Town, South Africa

4: David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

**§Contact information:** Dvora Leah Joseph Davey, Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, 615 E Charles Young Drive S, Los Angeles, CA 90095. [dvoradavey@ucla.edu](mailto:dvoradavey@ucla.edu), +1 (310) 701-1526

**Keywords:** pre-exposure prophylaxis, PrEP, PMTCT, pregnant, breastfeeding, South Africa, adherence, persistence

## Abstract

**Introduction:** Oral pre-exposure prophylaxis (PrEP) is a safe and effective prevention strategy to reduce women's risk of HIV in pregnancy and postpartum. Effective PrEP requires daily PrEP adherence, but little is known about maternal PrEP continuation and risk factors that influence optimal PrEP use.

**Methods:** The PrEP in pregnancy and postpartum (PrEP-PP) study is an ongoing cohort study that enrolled consenting pregnant, HIV-uninfected women at first antenatal care (ANC) visit, followed through 12-months postpartum. HIV-uninfected women and girls  $\geq 16$ -years who were eligible for the study received HIV prevention counseling and were offered PrEP. Interviewers collected socio-demographic, behavioral data from participants at each visit. We analyzed the proportion of women who initiated PrEP and the proportion who continued on PrEP after 3-months with associated correlates, including side effects whilst on PrEP, by estimating the prevalence ratio (95% CI) adjusting for *a priori* confounders.

**Results:** Between Aug'19 and Feb'21, we enrolled 891 pregnant women (median gestation=21wks; age=26yrs). Following PrEP counseling, 90% of women initiated PrEP at their first ANC visit (n=801); 60% were married or cohabiting. Three-quarters of women on PrEP returned for a repeat prescription at 1-month; 62% returned at 3-months. One-third of women on PrEP reported a side effect, mostly nausea/vomiting, dizziness, and headache. Women on PrEP in the 1<sup>st</sup> or 2<sup>nd</sup> trimester had higher odds of reporting side effects (aOR=2.61; 95%CI=1.17-5.84) vs. postpartum women. Women who reported side effects continued with PrEP less than those who did not report side effects (aPR=0.88; 95% CI=0.78-0.99) adjusting for covariates. Women who had  $\geq 1$  previous pregnancy (aPR=0.76;95%CI=0.59-1.00) or were postpartum (aPR=0.86;95%CI=0.75-0.99) continued less than women who were primigravid or pregnant. Women who reported having an HIV+ partner (aPR= 1.70;95% CI=1.55-1.86) or unknown partner serostatus (aPR=1.14;95%CI=1.01-1.29) were more likely to continue on PrEP than those who had HIV-negative partners.

**Conclusion:** PrEP initiation and early continuation were high in ANC in this setting. Being postpartum and experiencing side effects were associated with lower PrEP continuation, presenting an opportunity for improved clinical management and counseling during pregnancy of nausea/vomiting to address early, transient side effects. Interventions for postpartum women on PrEP are urgently needed.

**Clinical Trial Number:** NCT03826199

## Introduction

Women in sub-Saharan Africa face a high risk of HIV acquisition during pregnancy and the breastfeeding period.(1) Evidence suggests that HIV acquisition risk more than doubles for women during pregnancy and breastfeeding.(2) While the elimination of mother-to-child transmission (EMTCT) services have expanded rapidly in the region, few prevention interventions exist for the majority of pregnant women who initially test HIV-negative in antenatal care (ANC).(3, 4) This is a major missed opportunity that has implications for women, their partners, and infants. Among women living with HIV, acute maternal HIV infection during pregnancy and breastfeeding substantially increases the risk of vertical transmission.(5) According to recent mathematical modelling, South Africa expects over 76,000 infant HIV cases between 2020 and 2030.(6, 7) These models demonstrated that pre-exposure prophylaxis (PrEP) provision may reduce perinatal HIV by 41% if 80% of *all* HIV-uninfected pregnant women use PrEP in pregnancy and breastfeeding.(6)

PrEP is a promising intervention to prevent HIV acquisition, with benefits both to the individual and population-level health. The World Health Organization (WHO) recommends offering PrEP to pregnant and postpartum women at risk for HIV acquisition as an individual-controlled prevention strategy.(8-10) Currently, PrEP counselling and services for cis-gender women, including those who are pregnant or breastfeeding, remain limited. Outside sub-Saharan Africa, most PrEP programmes are focused on men who have sex with men (MSM). The United States (US), Kenya, and South Africa have the greatest use of PrEP by women. Although over 300,000 people globally initiated PrEP since 2012, only a minority of them were women. (11)

A recent systematic review found that there is no safety-related rationale for prohibiting PrEP during pregnancy and/or breastfeeding.(7) There is minimal penetration of tenofovir (the metabolite of tenofovir disoproxil fumarate [TDF]) into breastmilk.(12) While safety data are reassuring, more data on how best to provide and optimize PrEP use in pregnancy and the postpartum period are needed. Oral PrEP is a safe and effective prevention strategy to reduce women's risk of HIV in pregnancy and postpartum. There are multiple large-scale PrEP in pregnancy programs ongoing in South Africa and Kenya.(7, 13, 14). Effective PrEP requires daily PrEP adherence, but little is known about how minor symptoms, which may be more common during pregnancy, overlap with PrEP side effects and could impact PrEP persistence.

PrEP adherence and continuation have been low in women in South Africa,(15-19) and interventions are needed to improve PrEP uptake and adherence, especially in women at risk of HIV acquisition during pregnancy and breastfeeding.(20) There are numerous barriers to optimal maternal PrEP use in women across health facility-, intrapersonal-, and interpersonal-levels of population health. Common side effects, including gastrointestinal side effects (i.e. nausea, vomiting, diarrhoea) or dizziness are common in the early stages of taking PrEP. In Kenya, a frequent reason for discontinuation of PrEP in pregnant women (13) and adolescent girls and young women (AGYW) were side effects and low HIV risk perception (21). A recent meta-analysis of PrEP scale-up research in sub-Saharan Africa demonstrated that side effects were a key influence on PrEP use. (22)

To offer women additional choices to daily oral PrEP, alternative modalities are being evaluated, including long-acting injectables and intra-vaginal rings. Data from the HPTN084 trial showed a clear protective benefit from cabotegravir long-acting PrEP, with an 89 percent risk reduction compared to oral PrEP. The HPTN 084 trial will

follow women who conceive in the study to evaluate the safety of cabotegravir in pregnant and breastfeeding women to inform PrEP in pregnancy studies. However, interventions to ensure high adherence are essential in daily TDF/FTC, vaginal rings, and in 3-monthly doses because of the long drug tail that could increase drug resistance in the case of skipped doses.(23)

Our study evaluated early PrEP initiation and continuation in a maternal PrEP cohort in a busy antenatal clinic in Cape Town, South Africa. We evaluated correlates of PrEP initiation and continuation in a cohort of pregnant and breastfeeding women to inform the national rollout of maternal PrEP programs in South Africa. Specifically, we evaluated the hypothesis that common side effects in pregnancy among women on PrEP may be a barrier to optimal PrEP use in pregnant women in our PrEP in pregnancy cohort in South Africa. Raising awareness on PrEP side effects amongst pregnant women and their healthcare providers, minimizing gaps in side effect management, and ensuring adherence and persistence of PrEP during periods of risk are critical issues if PrEP can have a meaningful impact on reducing HIV incidence in pregnant and breastfeeding women. Planning for, proposing, and promoting optimal PrEP use necessitates a deeper understanding of user barriers, including side effects, to ensure successful interventions.

## Methods

The PrEP-PP (PrEP in Pregnant and Postpartum women) study is an ongoing open prospective cohort that enrolls consenting pregnant, HIV-uninfected adolescent girls and women (age  $\geq 16$  years) at the first ANC visit and follows participants through 12-months post-delivery from one public health clinic in Cape Town, Western Cape, South Africa. Recruitment began in August 2019 and is ongoing (N=891 as of February 28, 2021), with a planned sample size of 1,200 women.

**Study participants:** Study eligibility criteria include: 1) age of  $\geq 16$  years, 2) confirmed HIV-negative serostatus by a 4<sup>th</sup> generation antigen/antibody combination HIV test, 3) confirmed pregnancy status, 4) intention to stay in Cape Town through the postpartum period, 5) absence of contraindications to PrEP. Health care providers at study facilities provide group counselling to all pregnant women at baseline, which includes information on HIV testing and counselling, antiretroviral therapy (ART) for EMTCT, and the importance of HIV prevention for women who are HIV-uninfected. Eligible, consenting participants received 120 Rand (approximately \$8 USD) in grocery vouchers for their time and effort in the study, as well as remuneration for transportation costs.

**Data collection:** Following South African HIV testing guidelines, HIV counsellors provided ANC attendees without previous HIV diagnosis with rapid HIV testing and post-test counselling. (25) Upon confirmation of HIV seronegative status, trained study staff approach women to introduce the HIV prevention study. Upon agreement to participate in the study, the participant consented to screen for study eligibility, which included a rapid HIV antigen/antibody test and an HBsAg test (Abbott Laboratories). Upon eligibility confirmation and unassisted study consent, participants completed the baseline visit survey, which took 30 to 45 minutes using REDCap, a secure, web-based database platform. (26,27) Participants also received individual counselling about HIV prevention in pregnancy, including PrEP, along with information on consistent and correct condom use, knowing her partner's HIV status (including referral for a male partner or couple's HIV testing and counselling), and risk of serodiscordance. At baseline, participants self-

collected a vaginal swab that is tested for *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG), and *Trichomonas vaginalis* (TV) using point of care testing (Cepheid, Inc., Sunnyvale, CA, US) and treatment was provided following National STI Guidelines. (28) Data presented is through November 2020 when we stopped point-of-care testing as Cepheid was unable to place the order for STI kits.

Following the baseline survey, the study interviewer provided information about what PrEP is and the benefits of taking PrEP. The interviewer then asked the participant if they were interested in starting PrEP and disclosed that hesitancy or disinterest in PrEP initiation would not impact study participation. For study participants who agreed to initiate PrEP, the study nurse drew blood to measure baseline creatinine levels, results for which are confirmed within 24-48 hours. The nurse provided the patient with a one-month supply of Truvada® (tenofovir disoproxil fumarate/emtricitabine [TDF-FTC]) and an invitation card to return in one month for follow up testing (after which participants received a three-month prescription to correspond with quarterly study follow-up visits). Participants who did not start PrEP received an invitation to return in three months for a quarterly study follow-up visit. Follow-up visits were every 3-months and coincided with ANC visits until birth and the first postpartum visit. Follow-up visits lasted approximately 20-30 minutes.

**Data collection:** Survey measures were collected at baseline and follow-up visits for all participants (on PrEP and not on PrEP). Survey measures included questions on: (a) basic demographic information and obstetric history (baseline only), (b) partner HIV status, (c) sexual behaviours in the past month and past week (including the number of sex partners, type of sex, frequency of sex and condom use), (d) substance use from the Alcohol Use Disorders Identification Test (AUDIT) (31) and Drug Use Disorders Identification Test (DUDIT) (32), (e) HIV risk perception, (f) intimate partner violence (using the WHO IPV scale (33,34)), (g) perceived partner, community and social support for PrEP, and (h) for PrEP users only, questions related to PrEP adherence according to self-report (seven-day and 30-day recall) and pill count measures, side effects, adverse events, severe adverse events and birth outcomes (after participants have given birth) at follow-up visits.

We defined PrEP initiation as accepting the initial PrEP prescription at baseline (first ANC visit). We defined PrEP continuation as receiving a PrEP prescription at both baseline and the three-month follow-up visit.

**Analyses:** As of February 28, 2021, we had recruited and enrolled 891 participants. We present distribution of PrEP initiation (PrEP prescription received or not at baseline), PrEP continuation at three months in those who initiated PrEP at baseline (returned to the three-month follow-up visit and received another PrEP prescription or missed the visit), including counts and percentages for categorical variables and median and interquartile range (IQR) for continuous variables.

We present demographic characteristics including age, education, and marital status. We also include gestational age in weeks at baseline, gravidity (number of prior pregnancies). We analyse sexual behaviour data, including partner HIV testing in the past year, partner HIV status, condom use at last sex, and number of sexual partners during pregnancy. Finally, we selected substance use characteristics including any drug or alcohol use in the last year before pregnancy using the AUDIT and DUDIT scales.

We assess potential confounders with directed acyclic graphs (DAGs) (Supplemental Material). Age, marital status, gestational age at baseline are included as *a priori* confounders in the multivariable analysis of PrEP initiation and continuation with the exposures and outcomes of interest (1. PrEP initiation at baseline, 2. PrEP continuation at three months, and 3. PrEP adherence at three months). We also present side effects reported in women on PrEP at 3 months and reasons for PrEP discontinuation by age (<24 years vs. ≥24 years).

We construct univariate and multivariable poisson regression models to evaluate correlates of PrEP initiation in pregnant women at baseline and PrEP continuation at 3-months using a two-tailed test to evaluate significance, with a significance threshold of  $p < 0.05$ . All statistical analyses were conducted with STATA v.15.

**Ethics:** The PrEP-PP study was approved by the Human Research Ethics Committee at the University of Cape Town (#297/2018) and by the University of California, Los Angeles Institutional Review Board (IRB#18-001622).

## Results

### Cohort characteristics

Between August 2019 and February 2021, we enrolled 891 pregnant women at their first ANC visit. The median age was 26 years (IQR 22-30) and the median gestational age was 21 weeks (IQR=14-31). Over half of women in the cohort had completed secondary school or higher ( $n=459$ , 52%). Almost all had one or more prior pregnancy ( $n=866$ , 97%). Fifty-six percent of participants who had a partner were cohabiting or married ( $n=499$ ) and 17% reported having more than 1 sex partner in the past 12 months ( $n=151$ ). Most women reported that their partner was HIV-negative (66%) or they didn't know their serostatus (33%). At baseline, 90% of women were sexually active during pregnancy ( $n=805$ ), of which 30% reported using a condom at last sex ( $n=264$ ). Overall, 13% of women reported experiencing emotional, physical or psychological intimate partner violence (IPV). Half reported alcohol and/or drug use in the past year prior to pregnancy (48%;  $n=430$ ). One-third of women were diagnosed with one or more STIs including CT, NG, and/or TV. (**Table 1**)

### PrEP initiation

Following PrEP counseling, 90% of women initiated PrEP at their first ANC visit ( $n=801$ ), including  $n=50$  young women 16-18 years old. Pregnant women who initiated PrEP at the first ANC visit had a lower level of education. Overall, 87% of women who had a secondary level of education initiated PrEP compared with 93% of women with a lower level education ( $p=0.01$ ). Women diagnosed with a STI were more likely to initiate PrEP at initiation (94% vs 90%;  $p=0.058$ ). Pregnant women who experienced IPV in the past year also initiated PrEP more than those who did not experience IPV (94% vs. 89%,  $p=0.11$ ), though this was not statistically significant.

### PrEP continuation

Overall, 75% of women on PrEP at baseline returned for a repeat prescription at 1-month ( $n=668$ ), and 62% returned and continued on PrEP at 3-months ( $n=393$  of 635 eligible for 3-month visit). Women who continued on PrEP did not differ by age, education, relationship status, or baseline gestational age. Pregnant and postpartum women who

continued on PrEP at 3 months tended to be higher risk in terms of experiencing IPV in the last year (74% continued vs. 60% who did not report recent IPV) and substance users (66% continued vs. 57% who did not report recent substance use;  $p=0.02$ ). Women who continued were predominately pregnant vs. postpartum, did not experience side effects, and were earlier in their pregnancy when they came for their first ANC visit and started PrEP. **(Table 2)**

Women who reported having a partner living with HIV were more likely to continue on PrEP (100% continued vs. 59% of those with HIV-negative partners (aPR= 1.70, 95% CI=1.55, 1.86), and 69% of those with partners of unknown serostatus (aPR= 1.14, 95% CI=1.01, 1.29). Reporting intimate partner violence or substance use in the past year were both associated with an increased likelihood of continuing on PrEP in pregnant and postpartum women (aPR for IPV=1.24, 95% CI=1.08, 1.44; aPR for substance use=1.16, 95% CI=1.02, 1.32). **(Table 3)**

### Side effects in pregnant women on PrEP

Overall, 210 women reported side effects at the 3-month follow up visit (48% of  $n=441$  who attended the visit). The most common side effects were nausea and vomiting, reported by 39% and 26% of women who reported side effects, respectively. Approximately one in four women who reported nausea, vomiting, or a headache said that it bothered them “some” or “a lot”. While fewer women reported dizziness (16%), diarrhoea (2%), or bad dreams/insomnia (1%), these side effects bothered all women “some” or “a lot”. **(Figure 1)**. After one-month of follow-up, women in the 1st or 2nd trimester who were on PrEP had the highest odds of reporting side effects (aOR=2.61; 95%CI=1.17-5.84) compared to postpartum women, adjusting for maternal age (not tabled). One-third of women who reported a side effect continued on PrEP at 3-months, compared with 41% in those who did not experience side effects (aPR=0.88; 95% CI=0.79, 0.88) adjusting for age, gestational age at baseline, and relationship status. Women who had  $\geq 1$  prior pregnancy (aPR=0.76; 95% CI=0.59, 1.00) or were postpartum (aPR=0.86; 95% CI=0.75, 0.99) discontinued PrEP more than women who were primigravid or who were pregnant.

### Reason for missing PrEP doses

Women who reported taking PrEP but missing 1 or more doses were asked why they missed their PrEP doses in the past month. Out of 261 pregnant women, the most common reasons cited were because of forgetting (32%), due to travel (31%), or experiencing side effects and/or feeling ill (25%). About 1% of women indicated fear of safety and 11% of pregnant women who missed a dose of PrEP noted study or time burden. The only reason that was significantly associated with non-continuation of PrEP was side effects in the past month ( $p=0.04$ ). None of the other reasons were associated with PrEP discontinuation. **(Figure 2)**

## Discussion

Our study is one of the first to integrate PrEP provision in ANC in a high HIV incidence community in South Africa. PrEP initiation was high in the ANC setting and especially among higher risk pregnant women, including those diagnosed with a STI at initiation. We identified important barriers to early PrEP continuation in pregnancy, including common side effects like nausea and vomiting that may be overlapping with pregnancy symptoms. In addition, we

identified a significant drop off in PrEP continuation among postpartum women who no longer returned to the same clinic for their regular ANC visit. These results present opportunities for improved clinical management and counseling during pregnancy of nausea and vomiting to normalize early, transient side effects to improve PrEP adherence in pregnant women. Other opportunities include PrEP integration into maternal childcare and pediatric care to continue offering PrEP and counseling in breastfeeding women at risk of HIV acquisition.

PrEP was offered to HIV-uninfected pregnant women at their first antenatal visit (over 90% of those who were eligible and opted to be in the study). Almost 70% of women continued taking PrEP at 3-months after starting ANC. This proportion was significantly lower in postpartum women who were no longer attending regular ANC visits compared to pregnant women. Significant issues with PrEP continuation have been identified in other studies, with 50% or more of clients discontinuing within the first one to six months of use at sites in Kenya, South Africa, and the United States (24, 25). However, this proportion is higher than other populations of non-pregnant adolescent girls and young women (25) and female sex workers in South Africa (26), or pregnant women in lower HIV prevalence settings like in Kisumu, Kenya, where 39% of women continued on PrEP after one month and 41% in a family planning programme (13, 21). Similar proportions of PrEP continuation have been observed in African women in heterosexual serodiscordant couples (27), and in heterosexual women in the United States (28).

Our study identified important correlates of PrEP initiation and continuation in pregnancy. Importantly, we found that one-fifth of pregnant women reported side effects while taking PrEP and about half of those said that the side effects bothered them. Management of nausea and vomiting in pregnancy may be an important driver of PrEP continuation, including counseling women on the transient nature of side effects in pregnancy. Trained HIV counselors advised women to take PrEP at night, when they did not have morning sickness, or at a different time than other multi-vitamins and folic acid which may also cause nausea.

Having a male partner with an unknown HIV serostatus was associated with HIV acquisition in pregnancy and breastfeeding (29). Approximately 67% of women in our cohort knew their partner's serostatus. Prior studies have shown that male partners are rarely engaged in pregnancy care or couples' HIV testing in South Africa.(30) Innovative strategies to improve partner HIV testing may also optimize PrEP use in pregnant women by improving women's awareness of her partner's HIV status. In a Kenyan study, 53% of women reported that her partner used an HIV self-test, which may improve risk assessment and PrEP use.(31) PrEP programmes should consider how best to integrate HIV self-testing for monitoring of HIV status in PrEP users, and to offer couples HIV testing and encourage mutual disclosure in pregnant and breastfeeding women.

The most common reason for pregnant women to discontinue taking PrEP was because of side effects and pill burden (e.g., forgetting or travelling) associated with daily PrEP intake. Side effects and stigma were also cited as the most common reason for other South African men who have sex with men and sex workers to discontinue taking PrEP.(24) Long-acting PrEP methods are currently being tested in pregnant and breastfeeding women. However, daily pills may be preferred by some women who want control over when they start or stop taking PrEP, or who do not want injectables like injection or vaginal ring. Therefore, addressing the common side effects in PrEP users is



essential to improving adherence. This consideration is essential in pregnant women who require daily dosing for efficacy, given that non-adherence is less forgiving than in postpartum women.(32)

Our study had several strengths. Integrating PrEP into a busy government community health center allowed us to understand how best to offer PrEP to HIV-uninfected pregnant women, and what common barriers exist for short-term continuation. However, our study has limitations as well. Firstly, we used trained study staff to provide counseling and nurses to prescribe PrEP which limits the real-life implementation in the health facility Secondly, there was a large proportion of women who were lost to follow up after initiating PrEP. This study may have underestimated factors like lack of stable transportation from women's residence to a health clinic, intimate partner violence, and the impact of the COVID-19 lockdown orders as other reasons for discontinuation. Finally, our study evaluated women returning for PrEP prescription as a proxy for PrEP continuation but it is not a measure of PrEP adherence. Future studies will evaluate tenofovir diphosphate levels to understand levels of objective adherence in this cohort.

## Conclusions

In conclusion, we found a significant proportion of pregnant women were interested in starting PrEP at their first antenatal visit, especially among higher risk pregnant women. Continuation on PrEP at 3-months was also high when compared to other South African populations but it was lower in postpartum women who do not return to the same facility for ANC visits, and in women who report side effects early on that overlap with pregnancy symptoms. Our study findings present opportunities for interventions to optimize PrEP use in pregnant and breastfeeding women, including improved counseling and clinical management around side effects to normalize early, transient side effects, and decentralized services to pediatric care or community services for postpartum, breastfeeding women.

<b>Table 1. Characteristics of pregnant women offered PrEP in ANC in Cape Town, South Africa (N=891)</b>									
	Total (n)	%	Initiated PrEP (n)	% (col)	% (row)	Did not initiate PrEP (n)	% (col)	% (row)	p-value
<b>TOTAL</b>	<b>891</b>	<b>100%</b>	<b>801</b>	<b>90%</b>		<b>90</b>	<b>10%</b>		
<b>Demographic characteristics</b>									
<b>Age (years)</b>									
16-18	55	6%	50	6%	91%	5	6%	9%	0.89
19-24	308	35%	273	34%	89%	35	39%	11%	
25-29	280	31%	255	32%	91%	25	28%	9%	
30-34	151	17%	135	17%	89%	16	18%	11%	
>=35	97	11%	88	11%	91%	9	10%	9%	
<b>Highest level of education</b>									
< Grade 12	432	48%	400	50%	93%	32	36%	7%	<b>0.01</b>
>= Grade 12	459	52%	401	50%	87%	58	64%	<b>13%</b>	
<b>Gravidity</b>									
Primigravida	25	3%	22	3%	88%	3	3%	<b>12%</b>	0.73
Multigravida	866	97%	779	97%	90%	87	97%	10%	
<b>Relationship status*</b>									
Cohabiting	499	56%	446	56%	89%	53	59%	11%	0.26
Not cohabiting	328	37%	301	38%	92%	27	30%	8%	
<b>Clinical characteristics</b>									
<b>Gestational age (weeks, median, IQR)**</b>									
<=20 weeks	375	42%	336	42%	90%	39	43%	10%	0.73
>20 weeks	515	58%	465	58%	90%	50	56%	10%	
<b>STI diagnosed (CT, NG, and/or TV)***</b>									
No STI	493	55%	442	55%	90%	51	57%	10%	<b>0.06</b>
STI diagnosed (CT, NG, TV)	244	27%	229	29%	94%	15	17%	6%	
<b>Behavioural risk factors</b>									
<b>Sexually active in pregnancy</b>									
Not sexually active	86	10%	79	10%	92%	7	8%	8%	0.53
Sexually active	805	90%	722	90%	90%	83	92%	10%	
<b>Condom use*</b>									
Had sex without a condom at last sex	602	68%	544	68%	90%	58	64%	10%	0.66
Had sex with a condom at last sex	264	30%	236	29%	89%	28	31%	11%	
<b>Sexual partners</b>									
1 sex partner in past 12m	740	83%	661	83%	89%	79	88%	11%	0.21
>1 sex partner in past 12m	151	17%	140	17%	93%	11	12%	<b>7%</b>	
<b>IPV</b>									
Did not experience IPV in past 12m	774	87%	691	86%	89%	83	92%	11%	0.11
Experienced IPV in past 12m	117	13%	110	14%	94%	7	8%	<b>6%</b>	
<b>Substance use</b>									
No alcohol or drug use in past 12m	461	52%	408	51%	89%	53	59%	11%	0.15
Drank alcohol or used drugs in past 12m	430	48%	393	49%	91%	37	41%	9%	
<b>Partner HIV tested in past 12m (baseline)*</b>									
Don't know	297	33%	269	33%	91%	28	31%	9%	0.79
HIV-negative	589	66%	527	66%	89%	62	69%	11%	
HIV-positive	5	1%	5	1%	100%	0	0%	0%	

\* in women who report sex partners; \*\* 1 missing; \*\*\* STI testing through Nov 2020 (missing n=154); **bold p<0.10**

**Table 2. Characteristics of pregnant women on PrEP who persisted on PrEP at 3-months in ANC in Cape Town, South Africa (n=635)**

	Total (n)	%	Continued on PrEP at 3-months (n)	% (col)	% (row)	Discontinued at PrEP at 3-months (n)	% (col)	% (row)	p-value
<b>Total</b>	<b>635</b>	<b>100</b>	<b>393</b>		<b>62%</b>	<b>242</b>		<b>38%</b>	
<b>Demographic characteristics</b>									
<b>Age (years)</b>									
16-18	39	6%	24	6%	62%	15	6%	38%	0.98
19-24	228	36%	142	36%	62%	86	36%	38%	
25-29	199	31%	120	31%	60%	79	33%	40%	
30-34	97	15%	61	16%	63%	36	15%	37%	
>=35	72	11%	46	12%	64%	26	11%	36%	
<b>Education</b>									
< Grade 12	315	50%	199	51%	63%	116	48%	37%	0.51
>= Grade 12	320	50%	194	49%	61%	126	52%	39%	
<b>Gravidity</b>									
Primigravida	15	2%	12	3%	80%	3	1%	20%	0.18
Multigravida	620	98%	381	97%	61%	239	99%	39%	
<b>Relationship status*</b>									
Cohabiting	361	57%	227	58%	63%	134	55%	37%	0.49
Not cohabiting	233	37%	140	36%	60%	93	38%	40%	
<b>Clinical characteristics</b>									
<b>Gestational age (weeks, median, IQR)</b>									
	21	15-30	20	14-29		23	15-32		
<=20 weeks	262	41%	172	44%	66%	90	37%	34%	0.10
>20 weeks	373	59%	221	56%	59%	152	63%	41%	
<b>STI diagnosed (CT, NG, and/or TV)</b>									
No STI	394	62%	242	62%	61%	152	63%	39%	0.97
STI diagnosed	216	34%	133	34%	62%	83	34%	38%	
<b>Side effects reported at last visit</b>									
Did not experienced side effects	231	36%	181	46%	78%	50	21%	22%	<b>0.03</b>
Experienced side effects	210	33%	145	37%	69%	65	27%	31%	
<b>Pregnancy status</b>									
Pregnant	411	65%	267	68%	65%	144	60%	35%	<b>0.03</b>
Postpartum (gave birth since last visit)	224	35%	126	32%	56%	98	40%	44%	
<b>Behavioural risk factors (baseline)</b>									
<b>Sexually active in pregnancy</b>									
Not sexually active	64	10%	39	10%	61%	25	10%	39%	0.87
Sexually active	571	90%	354	90%	62%	217	90%	38%	
<b>Condom use at last sex*</b>									
Condomless sex	425	67%	264	67%	62%	161	67%	38%	0.69
Used a condom	192	30%	116	30%	60%	76	31%	40%	
<b>Sexual partners</b>									
1 sex partner in past 12m	520	82%	320	81%	62%	200	83%	38%	0.70
>1 sex partner in past 12m	115	18%	73	19%	63%	42	17%	37%	
<b>IPV</b>									
Did not experience IPV in past 12m	546	86%	327	83%	60%	219	90%	40%	<b>0.01</b>
Experienced IPV in past 12m	89	14%	66	17%	74%	23	10%	26%	
<b>Substance use</b>									
No alcohol or drug use in past 12m	322	51%	185	47%	57%	137	57%	43%	<b>0.02</b>
Drank alcohol or used drugs in past 12m	313	49%	208	53%	66%	105	43%	34%	

<b>Partner HIV tested in past 12m (baseline)*</b>									
Don't know	208	32%	140	36%	67%	68	27%	33%	<b>0.04</b>
HIV-negative	423	67%	249	63%	59%	174	72%	41%	
HIV-positive	4	1%	4	1%	100%	0	0%	0	

\* Of those who reported having a recent partner

<b>Table 3. Correlates of PrEP continuation at 3 months among women who had initiated PrEP in ANC in Cape Town, South Africa (n=635)</b>								
	<b>PrEP non-continuers (n=242; 38%)</b>	<b>% (col)</b>	<b>PrEP continuers (n=393; 62%)</b>	<b>% (col)</b>	<b>Proportion of women in risk category who continued with PrEP</b>	<b>Row % (in those continuing)</b>	<b>Prevalence ratio (95% CI) in univariate model</b>	<b>Prevalence ratio (95% CI) in multivariable model</b>
<b>Demographic characteristics</b>								
<b>Age (years)</b>								
<24	77/242	32%	138/393	35%	138/215	64%	Ref	Ref
>=24	165/242	68%	255/393	65%	255/420	61%	0.95 (0.83, 1.07)	0.95 (0.83, 1.09)
<b>Education level</b>								
< Grade 12	116/242	48%	199/393	51%	199/315	63%	Ref	Ref
>= Grade 12	126/242	52%	194/393	49%	194/320	61%	0.96 (0.85, 1.08)	0.97 (0.85, 1.10)
<b>Gravidity</b>								
Primigravida	3/242	1%	12/393	3%	12/15	80%	Ref	Ref
Multigravida	239/242	99%	381/393	97%	381/620	61%	0.77 (0.59, 1.00)	0.76 (0.59, 1.00)
<b>Living status</b>								
Cohabiting	134/227	59%	227/367	62%	227/361	63%	Ref	Ref
Not cohabiting	93/227	41%	140/367	38%	140/233	60%	0.96 (0.84, 1.09)	0.95 (0.83, 1.09)
<b>Gestational age</b>								
<=20 weeks	90/242	37%	172/393	44%	172/262	66%	Ref	Ref
>20 weeks	152/242	63%	221/393	56%	221/373	59%	0.90 (0.80, 1.02)	0.91 (0.80, 1.03)
<b>Pregnancy status</b>								
Pregnant	144/242	59%	267/393	68%	267/411	65%	Ref	Ref
Postpartum	98/242	41%	126/393	32%	126/224	56%	0.87 (0.76, 0.99)	0.86 (0.75, 0.99)
<b>STI diagnosed (CT, NG, and/or TV)</b>								
No STI	152/235	65%	242/375	65%	242/394	61%	Ref	Ref
STI diagnosed	83/235	35%	133/375	35%	133/216	62%	1.00 (0.88, 1.14)	0.96 (0.83, 1.10)
<b>Side effects</b>								
None	50/115	43%	181/326	56%	181/231	78%	Ref	Ref
≥1 side effect	65/115	57%	145/326	44%	145/210	69%	0.88 (0.79 - 0.99)	0.88 (0.78, 0.99)
<b>Behavioural risk factors</b>								
<b>Sexually active in pregnancy</b>								
Not sexually active	25/242	10%	39/393	10%	39/64	61%	Ref	Ref
Sexually active	217/242	90%	354/393	90%	354/571	62%	1.02 (0.83, 1.25)	0.92 (0.75, 1.14)
<b>Condom use at last sex</b>								
Condomless sex	161/237	68%	264/380	69%	264/425	62%	Ref	Ref
Used condom	76/237	32%	116/380	31%	116/192	60%	0.97 (0.85, 1.12)	0.94 (0.82, 1.09)
<b>IPV at baseline in past 12m</b>								
No IPV	219/242	90%	327/393	83%	327/546	83%	Ref	Ref
Experienced IPV	23/242	10%	66/393	17%	66/89	74%	1.24 (1.08, 1.43)	1.24 (1.08, 1.44)

<b>Substance use at baseline in past 12m</b>								
No alcohol or drug use	137/242	57%	185/393	47%	185/322	57%	Ref	Ref
Drank alcohol or used drugs	105/242	43%	208/393	53%	208/313	66%	1.16 (1.02, 1.31)	1.16 (1.02, 1.32)
<b>Partner HIV status</b>								
HIV-negative	174/242	72%	249/393	63%	249/423	59%	Ref	Ref
HIV-positive	0/242	0%	4/393	1%	4/4	100%	1.70 (1.57, 1.84)	1.70 (1.55, 1.86)
Don't know	68/242	28%	140/393	36%	140/208	36%	1.14 (1.01, 1.29)	1.14 (1.01, 1.29)

Figure 1. Side effects reported by pregnant women on PrEP and proportion reporting side effect bothered them





Figure 2. Reasons for missing PrEP doses among Pregnant and Postpartum women at 3 months



## Competing interests

We received the study drug (Truvada®) from Gilead (California, USA) and STI test kits from Cepheid (California, USA).

## Authors' contributions

DJD designed the study, analyzed the data, wrote the first draft of the paper, and reviewed the manuscript following co-author revision

RM reviewed the study design, cleaned the data and analyzed the data

NM is the study coordinator who reviewed the study implementation, data collection, coding and analysis, and reviewed/revised study drafts

ML reviewed the study design, reviewed the study data analysis and revised the final manuscript

JM reviewed the study design, study data and revised the final manuscript

LGB reviewed the study design, study data and revised the final manuscript

PG reviewed the study design, study data and revised the final manuscript

TC designed the study, reviewed the study data and revised the final manuscript

LM designed the study, reviewed the study data and revised the final manuscript

## Acknowledgments

We would like to thank our study participants, PrEP-PP study staff and the City of Cape Town Department of Health staff.

**Funding:** This study was supported through grants from the National Institute of Mental Health (TC and LM; R01MH116771) and Fogarty International Center (DJD; K01TW011187).



## References

1. Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. *PLoS Med*. 2014;11(2):e1001608.
2. Thomson KA, Hughes J, Baeten JM, John-Stewart G, Celum C, Cohen CR, et al. Increased Risk of Female HIV-1 Acquisition Throughout Pregnancy and Postpartum: A Prospective Per-coital Act Analysis Among Women with HIV-1 Infected Partners. *J Infect Dis*. 2018.
3. Mofenson LM. Tenofovir Pre-exposure Prophylaxis for Pregnant and Breastfeeding Women at Risk of HIV Infection: The Time is Now. *PLoS Med*. 2016;13(9):e1002133.
4. Pintye J, Davey DLJ, Wagner AD, John-Stewart G, Baggaley R, Bekker LG, et al. Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework. *Lancet HIV*. 2020;7(8):e582-e92.
5. Johnson LF, Stinson K, Newell ML, Bland RM, Moultrie H, Davies MA, et al. The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother-to-child transmission of HIV. *J Acquir Immune Defic Syndr*. 2012;59(4):417-25.
6. Joseph Davey DL, Bekker LG, Gomba Y, Coates T, Myer L, Johnson LF. Modelling the potential impact of providing preexposure prophylaxis in pregnant and breastfeeding women in South Africa. *AIDS (London, England)*. 2019;33(8):1391-5.
7. Joseph Davey DL, Pintye J, Baeten JM, Aldrovandi G, Baggaley R, Bekker LG, et al. Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading? *Journal of the International AIDS Society*. 2020;23(1):e25426.
8. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. *Clin Infect Dis*. 2013;57(12):1773-81.
9. Ministry of Health NASCP. Guidelines on use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya 2016. Nairobi, Kenya; July 2016.
10. World Health Organization. WHO Technical brief: Preventing HIV during pregnancy and breastfeeding in the context of pre-exposure prophylaxis (PrEP). Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.; 2017.
11. Hodges-Mameletzis I, Fonner VA, Dalal S, Mugo N, Msimanga-Radebe B, Baggaley R. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions. *Drugs*. 2019;79(12):1263-76.
12. Mugwanya KK, Hendrix CW, Mugo NR, Marzinke M, Katabira ET, Ngure K, et al. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption. *PLoS Med*. 2016;13(9):e1002132.
13. Kinuthia J, Pintye J, Abuna F, Mugwanya KK, Lagat H, Onyango D, et al. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. *The lancet HIV*. 2020;7(1):e38-e48.
14. Davey DLJ, Knight L, Markt-Maloney J, Tsawe N, Gomba Y, Mashela N, et al. "I had made the decision, and no one was going to stop me" —Facilitators of PrEP adherence during pregnancy and postpartum in Cape Town, South Africa. *medRxiv*. 2020:2020.11.23.20236729.
15. Velloza J, Khoza N, Scorgie F, Chitukuta M, Mutero P, Mutiti K, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. *Journal of the International AIDS Society*. 2020;23(3):e25463.
16. Scorgie F, Khoza N, Baron D, Lees S, Harvey S, Ramskin L, et al. Disclosure of PrEP use by young women in South Africa and Tanzania: qualitative findings from a demonstration project. *Cult Health Sex*. 2020:1-16.
17. Janes H, Corey L, Ramjee G, Carpp LN, Lombard C, Cohen MS, et al. Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. *AIDS Res Hum Retroviruses*. 2018;34(8):645-56.
18. Thomson KA, Baeten JM, Mugo NR, Bekker LG, Celum CL, Heffron R. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. *Curr Opin HIV AIDS*. 2016;11(1):18-26.
19. Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J, et al. Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial. *Journal of acquired immune deficiency syndromes (1999)*. 2016;71(4):452-61.
20. Joseph Davey DL, Bekker LG, Gorbach PM, Coates TJ, Myer L. Delivering preexposure prophylaxis to pregnant and breastfeeding women in Sub-Saharan Africa: the implementation science frontier. *AIDS (London, England)*. 2017;31(16):2193-7.
21. Mugwanya KK, Pintye J, Kinuthia J, Abuna F, Lagat H, Begnel ER, et al. Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya. *PLoS Med*. 2019;16(9):e1002885.

22. Eakle R, Weatherburn P, Bourne A. Understanding user perspectives of and preferences for oral PrEP for HIV prevention in the context of intervention scale-up: a synthesis of evidence from sub-Saharan Africa. *J Int AIDS Soc.* 2019;22 Suppl 4(Suppl Suppl 4):e25306.
23. Organization WH. Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women 2020 [
24. Pillay D, Stankevitz K, Lanham M, Ridgeway K, Murire M, Briedenhann E, et al. Factors influencing uptake, continuation, and discontinuation of oral PrEP among clients at sex worker and MSM facilities in South Africa. *PLoS One.* 2020;15(4):e0228620.
25. Celum CL, Delany-Moretlwe S, Baeten JM, van der Straten A, Hosek S, Bukusi EA, et al. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. *J Int AIDS Soc.* 2019;22 Suppl 4(Suppl Suppl 4):e25298.
26. Eakle R, Gomez GB, Naicker N, Bothma R, Mbogua J, Cabrera Escobar MA, et al. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project. *PLoS Med.* 2017;14(11):e1002444.
27. Heffron R, Ngure K, Odoyo J, Bulya N, Tindimwebwa E, Hong T, et al. Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. *Gates Open Res.* 2017;1:3.
28. Blackstock OJ, Patel VV, Felsen U, Park C, Jain S. Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinic. *AIDS Care.* 2017;29(7):866-9.
29. Pintye J, Drake AL, Kinuthia J, Unger JA, Matemo D, Heffron RA, et al. A Risk Assessment Tool for Identifying Pregnant and Postpartum Women Who May Benefit From Preexposure Prophylaxis. *Clin Infect Dis.* 2017;64(6):751-8.
30. Kilembe W, Wall KM, Mokgoro M, Mwaanga A, Dissen E, Kamusoko M, et al. Implementation of couples' voluntary HIV counseling and testing services in Durban, South Africa. *BMC Public Health.* 2015;15:601.
31. Pintye J, Drake AL, Begnel E, Kinuthia J, Abuna F, Lagat H, et al. Acceptability and outcomes of distributing HIV self-tests for male partner testing in Kenyan maternal and child health and family planning clinics. *Aids.* 2019;33(8):1369-78.
32. Stranix-Chibanda L, Anderson PL, Kacaneck D, Hosek S, Huang S, Nematadzira TG, et al. Tenofovir diphosphate concentrations in dried blood spots from pregnant and postpartum adolescent and young women receiving daily observed pre-exposure prophylaxis in sub-Saharan Africa. *Clin Infect Dis.* 2020.